Rolf Brekken

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. ncbi SPARC: a matricellular regulator of tumorigenesis
    Shanna A Arnold
    Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology and Departments of Surgery and Pharmacology, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390 8593 USA
    J Cell Commun Signal 3:255-73. 2009
  2. ncbi Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer
    Niranjan Awasthi
    Division of Surgical Oncology, Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    BMC Cancer 11:15. 2011
  3. ncbi GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer
    Kristi D Lynn
    Division of Surgical Oncology, Department of Surgery, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 76259, USA
    BMC Cancer 10:397. 2010
  4. ncbi The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
    Sean P Dineen
    Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, TX 75390 8593, USA
    BMC Cancer 8:352. 2008

Research Grants

  1. Matricellular proteins as regulators of tumor progression
    Rolf Brekken; Fiscal Year: 2007
  2. Matricellular proteins as regulators of tumor progression
    Rolf A Brekken; Fiscal Year: 2010

Collaborators

  • Thomas J Kodadek
  • Niranjan Awasthi
  • Kristi D Lynn
  • Shanna A Arnold
  • Sean P Dineen
  • Roderich E Schwarz
  • Margaret A Schwarz
  • Amanda Kirane
  • Jason E Toombs
  • D Gomika Udugamasooriya
  • Christina L Roland
  • Diego H Castrillon
  • Juliet G Carbon
  • Roni Mamluk
  • Laura A Sullivan
  • Adam W Beck
  • Andrew F Miller
  • Henry Wong

Detail Information

Publications4

  1. ncbi SPARC: a matricellular regulator of tumorigenesis
    Shanna A Arnold
    Hamon Center for Therapeutic Oncology Research, Division of Surgical Oncology and Departments of Surgery and Pharmacology, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390 8593 USA
    J Cell Commun Signal 3:255-73. 2009
    ..We aim to provide insight into how a matricellular protein such as SPARC might generate paradoxical, yet relevant, tumor outcomes in order to unify an apparently incongruent collection of scientific literature...
  2. ncbi Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer
    Niranjan Awasthi
    Division of Surgical Oncology, Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    BMC Cancer 11:15. 2011
    ..Smac is an endogenous IAP-antagonist, which renders synthetic Smac mimetics attractive anticancer agents. We evaluated the benefits of combining a Smac mimetic, JP1201 (JP), with conventional chemotherapy agents used for PDAC management...
  3. ncbi GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer
    Kristi D Lynn
    Division of Surgical Oncology, Department of Surgery, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 76259, USA
    BMC Cancer 10:397. 2010
    ..We have reported previously the development of an antagonistic VEGFR2 peptoid (GU40C4) that has promising anti-angiogenic activity in vitro and in vivo...
  4. ncbi The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
    Sean P Dineen
    Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, TX 75390 8593, USA
    BMC Cancer 8:352. 2008
    ..This small protein is based on a human fibronectin domain and has beneficial properties in that it is fully human, stable, and is produced in bacteria. CT-322 binds to and inhibits activation of VEGFR2...

Research Grants4

  1. Matricellular proteins as regulators of tumor progression
    Rolf Brekken; Fiscal Year: 2007
    ....
  2. Matricellular proteins as regulators of tumor progression
    Rolf A Brekken; Fiscal Year: 2010
    ....